BUZZ-PREVIEW: Johnson & Johnson rises ahead of quarterly earnings report

Shares of Johnson & Johnson JNJ.N close up 0.8% at $148.15 on Tues ahead of quarterly earnings report due before market open on Weds with investor's eyeing the drug maker's pipeline and its proposed talc powder settlement

JNJ is expected to report rev of $22.4 bln, up nearly 5% from a year ago, and a 12% slump in adj EPS to $2.01

JNJ's rev has met expectations 6 times over the last 8 quarters while EPS met estimates every time

Among the 24 analysts that cover JNJ, avg rating is "buy" and their median PT is $172.50, per LSEG data

A JNJ unit filed for bankruptcy for a third time in Sept as the healthcare giant sought to advance a proposed $10 bln settlement that would end tens of thousands of lawsuits alleging that the company's baby powder and other talc products caused cancer

Last month, U.S. Food and Drug Administration declined to approve an injectable version of JNJ's drug Rybrevant for a type of lung cancer

JNJ shares up 2.4% YTD compared with the S&P 500 healthcare index's .SPXHC 3.5% advance to begin 2025

(Reporting by Chibuike Oguh in New York)

((Chibuike.Oguh@thomsonreuters.com; +332-219-1834; Reuters Messaging: chibuike.oguh.thomsonreuters.com@reuters.net/))